These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30887844)

  • 1. FOLFOXIRI plus biologics in advanced colorectal cancer.
    García-Alfonso P; Torres G; García G; Gallego I; Ortega L; Sandoval C; Muñoz A; Lloansí A
    Expert Opin Biol Ther; 2019 May; 19(5):411-422. PubMed ID: 30887844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
    Satake H; Tsuji A; Nakamura M; Ogawa M; Kotake T; Hatachi Y; Yasui H; Takagane A; Okita Y; Nakamura K; Onikubo T; Takeuchi M; Fujii M
    Int J Clin Oncol; 2018 Jun; 23(3):490-496. PubMed ID: 29464396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
    Folprecht G; Martinelli E; Mazard T; Modest DP; Tsuji A; Esser R; Cremolini C; Falcone A
    Cancer Treat Rev; 2022 Jan; 102():102301. PubMed ID: 34839118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
    Bendell JC; Zakari A; Peyton JD; Boccia R; Moskowitz M; Gian V; Lipman A; Waterhouse D; LoCicero R; Earwood C; Lane CM; Meluch A
    Oncologist; 2016 Mar; 21(3):279-80. PubMed ID: 26911408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
    Antoniotti C; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Marmorino F; Moretto R; Prisciandaro M; Tamburini E; Tortora G; Passardi A; Bergamo F; Raimondi A; Ritorto G; Borelli B; Conca V; Ugolini C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Boni L; Galon J; Cremolini C
    J Clin Oncol; 2024 Aug; 42(22):2637-2644. PubMed ID: 38865678
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
    Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
    van Nassau SC; Bond MJ; Scheerman I; van Breeschoten J; Kessels R; Valkenburg-van Iersel LB; Verheul HM; Buffart TE; Mekenkamp LJ; Lemmens VE; Koopman M; Bol GM;
    JAMA Netw Open; 2021 Sep; 4(9):e2124766. PubMed ID: 34505885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Leal F; Ferreira FP; Sasse AD
    Clin Colorectal Cancer; 2017 Dec; 16(4):405-409.e2. PubMed ID: 28433602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOXIRI Plus Panitumumab As First-Line Treatment of
    Modest DP; Martens UM; Riera-Knorrenschild J; Greeve J; Florschütz A; Wessendorf S; Ettrich T; Kanzler S; Nörenberg D; Ricke J; Seidensticker M; Held S; Buechner-Steudel P; Atzpodien J; Heinemann V; Seufferlein T; Tannapfel A; Reinacher-Schick AC; Geissler M
    J Clin Oncol; 2019 Dec; 37(35):3401-3411. PubMed ID: 31609637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
    Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
    Hu H; Wang K; Huang M; Kang L; Wang W; Wang H; Qiu M; Lin R; Zhang H; Lan P; Wu X; Liu G; Wan Y; Liu M; Zhou Z; Huang Y; Li F; Zhang J; Cai Y; Ma T; Zhou J; Wang H; Ling J; Cai Y; Wu Z; Luo S; Ling L; Deng Y
    Oncologist; 2021 Jan; 26(1):e90-e98. PubMed ID: 33400355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.